Therapy Areas: Cardiovascular
Destiny Pharma's XF-73 nasal gel reduces antibiotic use in cardiac surgery patients
22 July 2024 - Destiny Pharma plc (AIM: DEST), a clinical-stage biotechnology company, announced on Monday significant findings from its Phase 2b trial of XF-73 Nasal Gel in cardiac surgery patients. ...
CereVasc names new directors
17 July 2024 - CereVasc Inc, a US-based clinical-stage medical device company developing novel treatments for neurological diseases, announced on Tuesday the appointment of Shlomi Nachman and Timothy ...
AstraZeneca completes acquisition of Amolyt Pharma
15 July 2024 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has successfully finalised its acquisition of Amolyt Pharma, a clinical-stage biote...
CureLab Oncology names new CMO
12 July 2024 - CureLab Oncology, a clinical-stage biotech company, announced on Thursday that it has named Dr Aubrey C Galloway as its new chief medical officer (CMO).In the new role, Dr Galloway will...
Tempus announces receipt of FDA clearance for AI-based AFib risk detection
26 June 2024 - Precision medicine company Tempus AI Inc (NASDAQ: TEM) announced on Wednesday that it has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AI-based Temp...
Revelation Biosciences' Phase 1 study shows promising results for TLR4 agonist Gemini
24 June 2024 - Revelation Biosciences Inc (NASDAQ: REVB), a clinical-stage life sciences company, on Monday announced positive safety and biomarker data from its Phase 1 clinical study of Gemini (RVL-...